Form 15-12G - Securities registration termination [Section 12(g)]
02 Février 2024 - 11:23PM
Edgar (US Regulatory)
|
UNITED
STATES |
OMB
APPROVAL |
|
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
15 |
OMB
Number: 3235-0167
Expires: July
31, 2024 Estimated average burden
hours per response 1.50 |
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number 000-55453
Endonovo
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
6320
Canoga Avenue, 15th Floor, Woodland Hills, CA 91367
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common
Stock, par value $0.0001
(Title
of each class of securities covered by this Form)
None
(Titles
of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1) |
☐ |
|
Rule 12g-4(a)(2) |
☒ |
|
Rule 12h-3(b)(1)(i) |
☐ |
|
Rule 12h-3(b)(1)(ii) |
☐ |
|
Rule 15d-6 |
☐ |
|
Rule 15d-22(b) |
☐ |
|
Approximate number of holders of record as of the certification
or notice date: |
426 |
|
Pursuant
to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this
certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date: |
February
2, 2024 |
|
By: |
/s/
Alan Collier |
|
|
|
|
Alan
B. Collier, CEO |
SEC 2069 (08-11) |
Potential persons who are to respond to the collection of information
contained in this Form are not required to respond unless the Form displays a currently valid OMB control number. |
Instruction:
This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act
of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed
by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form
shall be typed or printed under the signature.
Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Endonovo Therapeutics (PK) (USOTC:ENDV)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
Real-Time news about Endonovo Therapeutics Inc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Endonovo Therapeutics Inc (PK)